Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy.

Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become standard of care for certain types of cancers. However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies. Combination therapy strategies are currently under intensive investigation in the clinic, including the combination of PD-1/PD-L1 agents with IDO1 inhibitors. Here, we report the discovery of a class of IDO1 heme-binding inhibitors featuring a unique amino-cyclobutarene motif, which was discovered through SBDD from a known and weakly active inhibitor. Subsequent optimization efforts focused on improving metabolic stability and were greatly accelerated by utilizing a robust SNAr reaction of a facile nitro-furazan intermediate to quickly explore different polar side chains. As a culmination of these efforts, compound 16 was identified and demonstrated a favorable overall profile with superior potency and selectivity. Extensive studies confirmed the chemical stability and drug-like properties of compound 16, rendering it a potential drug candidate.

[1]  Giulia Caron,et al.  Intramolecular hydrogen bonding: An opportunity for improved design in medicinal chemistry , 2019, Medicinal research reviews.

[2]  Lu Chen,et al.  Process Safety Considerations for the Supply of a High-Energy Oxadiazole IDO1-Selective Inhibitor , 2019, Organic Process Research & Development.

[3]  A. Sahebkar,et al.  Targeting indoleamine‐2,3‐dioxygenase in cancer: Scientific rationale and clinical evidence , 2019, Pharmacology & therapeutics.

[4]  A. Pawlik,et al.  CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy , 2018, Expert opinion on investigational drugs.

[5]  G. Prendergast,et al.  Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond , 2018, Seminars in Immunopathology.

[6]  Micah T. Nelp,et al.  Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form , 2018, Proceedings of the National Academy of Sciences.

[7]  Klaus Urbahns,et al.  Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies , 2018, Angewandte Chemie.

[8]  A. Mondal,et al.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. , 2017, Trends in cancer.

[9]  G. Prendergast,et al.  Discovery of IDO1 Inhibitors: From Bench to Bedside. , 2017, Cancer research.

[10]  T. Poulos,et al.  Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1 , 2017, Nature Communications.

[11]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[12]  L. Brochez,et al.  The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. , 2017, European journal of cancer.

[13]  M. Bower,et al.  INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology , 2017, ACS medicinal chemistry letters.

[14]  Thomas Glarner,et al.  Handling Hydrogen Peroxide Oxidations on a Large Scale: Synthesis of 5-Bromo-2-nitropyridine , 2017 .

[15]  Edward G. Lorenzana,et al.  Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models , 2015, Journal of Immunotherapy for Cancer.

[16]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[17]  Axel Hoos,et al.  Big opportunities for small molecules in immuno-oncology , 2015, Nature Reviews Drug Discovery.

[18]  Olivier Michielin,et al.  Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. , 2015, Journal of medicinal chemistry.

[19]  E. Stepanova,et al.  A new preparative method and some chemical properties of 4-R-furazan-3-carboxylic acid amidrazones , 2015, Chemistry of Heterocyclic Compounds.

[20]  B. Cosimelli,et al.  The Boulton–Katritzky Reaction: A Kinetic Study of the Effect of 5‐Nitrogen Substituents on the Rearrangement of Some (Z)‐Phenylhydrazones of 3‐Benzoyl‐1,2,4‐oxadiazoles , 2014 .

[21]  Gregory Lizée,et al.  Harnessing the power of the immune system to target cancer. , 2013, Annual review of medicine.

[22]  C. Cramer,et al.  Use of solution-phase vibrational frequencies in continuum models for the free energy of solvation. , 2011, The journal of physical chemistry. B.

[23]  S. Grimme,et al.  A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. , 2010, The Journal of chemical physics.

[24]  B. Kuhn,et al.  Intramolecular hydrogen bonding in medicinal chemistry. , 2010, Journal of medicinal chemistry.

[25]  Qian Wang,et al.  Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.

[26]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[27]  D. Truhlar,et al.  The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals , 2008 .

[28]  F. Weigend,et al.  Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy. , 2005, Physical chemistry chemical physics : PCCP.

[29]  Gilchrist,et al.  Product Class 7: 1,2,5-Oxadiazoles , 2004 .

[30]  W. E. Billups,et al.  Cyclobutarenes and related compounds. , 2003, Chemical reviews.

[31]  A. Ghose,et al.  Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods , 1998 .